Literature DB >> 15163015

Cyclin D1 overexpression in AIDS-related and classic Kaposi sarcoma.

Angela Hong1, Stewart Davies, Graham Stevens, C Soon Lee.   

Abstract

The anatomic distribution and rate of progression vary significantly between acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS) and classic KS. The reasons are unclear, but cyclin D1 overexpression is associated with tumor progression in other malignancies. Cyclin D has an important regulatory role in the progression of cell cycle at the G1-S phase due to its effect in phosphorylating the retinoblastoma gene product. Forty-one paraffin-embedded surgical specimens (31 AIDS-related, 10 classic) were examined using streptavidin-biotin-peroxidase immunohistochemistry with monoclonal antibody to cyclin D1. A scoring system based on the intensity and extent of staining was used. The correlations among cyclin D1 expression and clinicopathologic parameters were statistically analyzed. Cyclin D1 overexpression was found in 29% (12/41) of all KS cases. There was a strong correlation between cyclin D1 overexpression and pathologic stage (0% in patch stage, 13% in plaque stage, 50% in nodular stage; P = 0.0017). Classic KS lesions had a higher incidence of cyclin D1 overexpression than AIDS-related lesions (70% vs 16%, P = 0.001). Cyclin D1 overexpression was detected in 78% of the classic nodular lesions and 31% of the AIDS-related nodular lesions (P = 0.03). On multivariate analysis, negative human immunodeficiency virus status (P = 0.001) and nodular lesions (P = 0.007) were strong predictors of cyclin D1 overexpression. Age, gender, recurrence of the tumor, multiplicity, and site of the lesions hold no statistically significant association with cyclin D1 expression on multivariate analysis. In summary, cyclin D1 overexpression was more prevalent in classic lesions and more advanced nodular stage. These findings raise the possibility of a different pathogenetic mechanism in the progression of AIDS-related KS and classic KS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163015     DOI: 10.1097/00129039-200403000-00005

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  5 in total

Review 1.  Diagnosis and Treatment of Kaposi Sarcoma.

Authors:  Johann W Schneider; Dirk P Dittmer
Journal:  Am J Clin Dermatol       Date:  2017-08       Impact factor: 7.403

2.  Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement.

Authors:  Cheng-Han Lee; Rola H Ali; Marjan Rouzbahman; Adrian Marino-Enriquez; Meijun Zhu; Xiangqian Guo; Alayne L Brunner; Sarah Chiang; Samuel Leung; Nataliya Nelnyk; David G Huntsman; C Blake Gilks; Torsten O Nielsen; Paola Dal Cin; Matt van de Rijn; Esther Oliva; Jonathan A Fletcher; Marisa R Nucci
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

3.  Kaposi's sarcoma-associated herpesvirus G-protein coupled receptor activates the canonical Wnt/β-catenin signaling pathway.

Authors:  Magdalena Angelova; MaryBeth Ferris; Kenneth F Swan; Harris E McFerrin; Gabriella Pridjian; Cindy A Morris; Deborah E Sullivan
Journal:  Virol J       Date:  2014-12-17       Impact factor: 4.099

Review 4.  Biomarkers of HIV-associated Cancer.

Authors:  Brian Thabile Flepisi; Patrick Bouic; Gerhard Sissolak; Bernd Rosenkranz
Journal:  Biomark Cancer       Date:  2014-07-03

5.  CyclinD1, a prominent prognostic marker for endometrial diseases.

Authors:  Shuo Liang; Kun Mu; Yan Wang; Zhiqiang Zhou; Juan Zhang; Yan Sheng; Tingguo Zhang
Journal:  Diagn Pathol       Date:  2013-08-15       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.